Harpal Sandhu, MD, FRCSC, discusses the preclinical performance of XPK-640 and how Optigo’s hyaluronic acid-anchoring platform may reshape dosing expectations in retinal disease.
Harpal Sandhu, MD, FRCSC
Advertisement
Harpal Sandhu, MD, FRCSC, is in private practice with Retina Northwest, and clinical instructor in ophthalmology at Oregon Health and Science University in Portland.
Articles by Harpal Sandhu, MD, FRCSC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
2
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
3
AAO 2025: A study of retinal vasculitis events with intravitreal agents
4
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
5
.png "Optometry Times"){kind=logo}
